Emergent Biosolutions And University Of Oxford Form Joint Venture To Develop An Advanced Tuberculosis Vaccine
The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) has announced that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the "Consortium"), to further develop MVA85A, the world's most clinically advanced vaccine candidate for the prevention of tuberculosis.
(more...)
(more...)
